Section : Conference Notes

Poster – Ertapenem in the Treatment of Severe Hidradenitis Suppurativa

Poster – Ertapenem in the Treatment of Severe Hidradenitis Suppurativa


  • Verneuil’s disease is a poorly understood condition where the available treatments are quite often unsatisfactory. The authors demonstrate the efficacy of a large spectrum (also targets anaerobic germs) antibiotic called Etrapenem.
  • The drug is administered intraveinously (central brachial catheter) at a dose of 1g/day for a duration of 4 to 6 weeks (5.5 weeks +/- 1.3).
  • The treatment is followed by an oral course of an antibiotic combination of rifampicin-moxifloxacin-métronidazole.
  • The retrospective study includes 26 patients (34 years +/-14). 16 patients were classified as having severity of disease as stage 2 according to Hurley’s classification and 10 patients had stage 3.


  • Results show an improvement in all cases with:
  1. a decrease of pain from 6.3 (+/- 2.3) to 1 (+/- 1.5) (p smaller than 0.05) (Visual Analog Scale (VAS) from 0 to 10)
  2. the oozing reduced from 6.5 (+/- 2.9) to 1.7 (+/- 1.8) (p smaller than 0.05)
  3. an negative impact on daily life lowered from 7.4 (+/- 1.7) to 2.2 (+/- 2.1) (p smaller than 0.05).
  • One case of complete remission (disappearance of all inflammatory lesions) occured in a patient with a severity of stage 2 (of Hurley). A reduction of one stage of Hurley was observed in 7 patients with stage 2 ans also 7 patients with stage 3 of the disease.
  • The only noteworthy side effect is the development of oral and vaginal candidiasis in one third of treated patients. One case of thrombosis and on case of lymphangitis were observed.


The results are interesting and a prospective study will be able to validate or not these retrospective observations.


Dr Christophe HSU – dermatologist. Geneva, Switzerland

Source of information (French): Join-Lambert O, Nassif A et al. – Efficacité de l’ertapénème (1g/j) en traitement d’attaque dans l’hidrosadénite suppurée sévère. Hopital Necker Enfants Malades, Institut Pasteur, Paris, France